Pfizer, Servier Enter into Exclusive Global License, Collaboration Agreement to Co-develop and Commercialize UCART19

Cellectis

and Servier today announced that they signed an amendment to their existing collaboration agreement from February 2014 especially for UCART19, a TALEN® gene-edited allogeneic Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy. Under this amendment, Servier early exercises its option to acquire the exclusive worldwide rights to further develop and commercialize UCART19, which is about to enter Phase 1 development for chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). In addition, Pfizer Inc.

and Servier have entered into an exclusive global license and collaboration agreement to co-develop and commercialize UCART19. Under the terms